AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel by Sieuwerts, A.M. (Anieta) et al.
AR splice variants in circulating tumor cells of patients
with castration-resistant prostate cancer: relation with
outcome to cabazitaxel
Anieta M. Sieuwerts1,2 , Wendy Onstenk1, Jaco Kraan1, Corine M. Beaufort1, Mai Van1, Bram De
Laere3,4, Luc Y. Dirix3,4, Paul Hamberg5, Aart Beeker6, Hielke J. Meulenbeld7, Geert-Jan Creemers8,
Wytske M. van Weerden9, Guido W. Jenster9, Annemieke J. M. Nieuweboer1, Ron H. J.
Mathijssen1, Ronald de Wit1, John W. M. Martens1,2 and Stefan Sleijfer1
1 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 Department of Medical Oncology, Cancer Genomics Netherlands, Rotterdam, The Netherlands
3 GZA Hospitals Sint-Augustinus, Wilrijk, Belgium
4 Center for Oncological Research, University of Antwerp, Antwerp, Belgium
5 Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands
6 Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands
7 Department of Internal Medicine, Gelre Ziekenhuizen, Zutphen, The Netherlands
8 Department of Internal Medicine, Catharina Ziekenhuis, Eindhoven, The Netherlands
9 Department of Urology, Erasmus MC, Rotterdam, The Netherlands
Keywords
androgen receptor; AR splice variants;
cabazitaxel; castration-resistant prostate
cancer; circulating tumor cells
Correspondence
A. M. Sieuwerts, Erasmus MC Cancer
Institute, Department of Medical Oncology
and Cancer Genomics Netherlands,
Wytemaweg 40, 3015 GD, Rotterdam, The
Netherlands
Tel: 0031 10 7044 372
E-mail: a.sieuwerts@erasmusmc.nl
Anieta M. Sieuwerts, Wendy Onstenk, John
W. M. Martens and Stefan Sleijfer
contributed equally to this work
(Received 24 March 2019, revised 1 June
2019, accepted 7 June 2019, available
online 28 June 2019)
doi:10.1002/1878-0261.12529
The androgen receptor splice variant (AR-V) 7 in circulating tumor cells
(CTCs) is a predictor for resistance to anti-AR-targeted treatment, but not
to taxane-based chemotherapy in metastatic castration-resistant prostate
cancer (mCRPC). In this study, we investigated whether the presence of
two constitutively active variants (AR-V3, AR-V7) and two other condi-
tionally activated variants (AR-V1, AR-V9) vs full-length androgen recep-
tor (AR-FL) measured in CTCs from patients with mCRPC were
associated with outcome to therapy with the taxane cabazitaxel. Blood was
collected at baseline and after two cycles of cabazitaxel from 118 mCRPC
patients starting cabazitaxel in a prospective phase II trial. CellSearch-en-
riched CTCs were enumerated and in parallel characterized for the pres-
ence of the AR-Vs by reverse transcription quantitative polymerase chain
reaction. Correlations with CTC and prostate-specific antigen response to
cabazitaxel as well as associations with overall survival (OS) were investi-
gated. All AR-Vs were frequently present and co-expressed at frequencies
of 31–48% at baseline and at 19–40% after two cycles of cabazitaxel. No
specific directions of change in the measured variants were detected
between the start of treatment and after two cycles of cabazitaxel. No asso-
ciations between the presence of AR-V3 and AR-V7 and outcome to cabaz-
itaxel were observed. While a reduction in CTCs to < 5 CTCs during
treatment (CTC5-response) was less often observed in patients with AR-
V9-positive CTCs at baseline (P = 0.004), the CTC5-adjusted detection of
AR-V1 after two cycles of cabazitaxel was an independent prognostic
Abbreviations
AR, androgen receptor; AR-FL, full-length androgen receptor; AR-V(1/3/7/9), androgen receptor splice variant (1/3/7/9, ); cDNA,
complementary deoxyribonucleic acid; Cq, cycle threshold for quantification; CRPC, castration-resistance prostate cancer; CTC, circulating
tumor cell; HR, hazard ratio; IQR, interquartile range; LOD, limit of detection; LOQ, limit of quantification; mCRPC, metastatic castration-
resistant prostate cancer; mRNA, messenger ribonucleic acid; OS, overall survival; PSA, prostate-specific antigen; RR, response rate; RT–
qPCR, reverse transcription quantitative polymerase chain reaction; SD, standard deviation.
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factor for OS [HR 2.4 (95% CI 1.1–5.1, P = 0.03)]. These novel findings
are expected to contribute to more personalized treatment approaches in
mCRPC patients.
1. Introduction
The presence of the androgen receptor (AR) splice
variant (AR-V) 7 in circulating tumor cells (CTCs) was
recently shown to predict resistance to new-generation
anti-AR-targeted treatments (abiraterone acetate and
enzalutamide), but not to taxane-based chemotherapy
in patients with metastatic castration-resistant prostate
cancer (mCRPC) (Antonarakis et al., 2015; Antonara-
kis et al., 2017; Antonarakis et al., 2014; De Laere
et al., 2017; De Laere et al., 2019; Nakazawa et al.,
2015; Onstenk et al., 2016; Onstenk et al., 2015; Scher
et al., 2018; Scher et al., 2017; Scher et al., 2016;
Tagawa et al., 2019). If further validated, like currently
ongoing in the CABA-V7 study (NCT03050866), the
AR-V7 status of CTCs may be used in clinical care to
select the best treatment for an individual patient at a
specific time (Sieuwerts et al., 2018).
Similar to the constitutively, ligand-independent,
active AR-V7, several other AR-Vs, including AR-V3
that lack the ligand-binding domain, have been identi-
fied. In addition, more cell-context-dependent variants
like AR-V1 and AR-V9, which like the full-length AR
(AR-FL) are conditionally activated variants, have
been described (Hu et al., 2009; Hu et al., 2011; Jern-
berg et al., 2017). The clinical relevance of these splice
variants to predict the type of response to taxane-
based chemotherapy in patients with mCRPC, how-
ever, remains to be established (Antonarakis et al.,
2016; De Laere et al., 2019).
In previous reports, we demonstrated in cases
included in the prospective CABARESC trial (Nieuwe-
boer et al., 2017) the feasibility of measuring the AR-
V7 status of CellSearch-enriched CTCs (Sieuwerts
et al., 2018) and showed that the presence of the con-
stitutively active AR-V7 variant at baseline had no
association with outcome to cabazitaxel chemotherapy
(Onstenk et al., 2015). In the current study, we used
our CellSearch-based assay to further investigate the
role of AR-V7 in CTCs in an extended series recruited
within the framework of the prospective CABARESC
trial (Nieuweboer et al., 2017). Besides AR-V7, we
determined the prevalence of another constitutively
active, ligand-independent, AR variant (AR-V3) and
two, like AR-FL, conditionally activated variants (AR-
V1 and AR-V9) in CTCs at baseline and after two
cycles of cabazitaxel. Finally, we investigated their
possible clinical relevance.
2. Patients and methods
2.1. Patients
As reported before (Onstenk et al., 2016; Onstenk
et al., 2015), patients with progressive mCRPC were
recruited from the multicenter prospective phase II
CABARESC trial (Dutch trial registry number
NTR2840) (Nieuweboer et al., 2017). In our pilot
study, we reported on 29 patients with ≥ 10 CTCs at
baseline (Onstenk et al., 2015). Here, we report on all
patients from the trial from which we had collected
CTCs. Full inclusion criteria are listed in Data S1.
Patients were randomized between three-weekly cabaz-
itaxel, 25 mgm2 with or without budesonide, a
locally active corticosteroid, during the first two treat-
ment cycles. No difference in overall survival (OS)
[log-rank (Mantel–Cox) P = 0.41] or incidence or
severity of cabazitaxel-induced diarrhea (Nieuweboer
et al., 2017) was seen between the two arms, and there-
fore, the budesonide treatment arm was only evaluated
as a stratification factor in the comparisons between
the patient groups with CTCs negative or positive for
the AR-Vs. The work described has been carried out
in accordance with Ethical Principles for Medical
Research Involving Human Subjects (World Medical
Association Declaration of Helsinki). The Erasmus
MC and the local Institutional Review Boards at sites
that collaborated in the study lent approval. All
patients provided written informed consent.
2.2. Blood sampling and processing
Blood for the CTC analyses was sampled in CellSave
[Menarini, Silicon Biosystems, Castel Maggiore (BO),
Italy] and EDTA tubes before the first and after the sec-
ond cycle of cabazitaxel. As described before (Onstenk
et al., 2015; Sieuwerts et al., 2018), CTCs were enumer-
ated and characterized from 7.5 mL peripheral CellSave
and EDTA blood, respectively, using the CellSearch
System (Menarini Silicon Biosystems). The CTC enu-
meration was performed in CellSave blood within 96 h
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after sampling and the characterization in EDTA blood
within 24 h after sampling. CellSearch-enriched CTCs
from the EDTA characterization tube were subjected to
RNA isolation using the AllPrep DNA/RNA Micro Kit
(Qiagen, Hilden, Germany) followed by complementary
deoxyribonucleic acid (cDNA) generation and pream-
plification of individual genes. Individual transcript
expression levels were measured using quantitative poly-
merase chain reaction (qPCR) applying the same proto-
col as described before (Onstenk et al., 2015; Sieuwerts
et al., 2018).
2.3. Validation processes of the qPCR assays
Details of the used TaqMan Gene Expression Assays
(Applied Biosystems, Carlsbad, CA, USA) can be found
in Table S1. Analytical validation data for each of the
AR-V measurements are given in Tables S2 toS4.
In brief, all qPCR assays performed with an equal
efficiency [slope log cDNA input vs cycle threshold for
quantification (Cq) value: 3.38 to 3.82]. The limit
of detection (LOD), defined as the lowest input of
RNA isolated from VCaP cells that could be reliably
identified as being qualitatively present in the sample,
was calculated to be the RNA equivalent of 0.03 (for
AR-WT) to 0.5 (for AR-V3) VCaP cells in the final
reverse transcription qPCR (RT–qPCR). The limit of
quantification (LOQ), defined as the lowest input of
RNA isolated from VCaP cells that could be repro-
ducibly quantified, was set at a CV of less than 25%
and calculated to be equal to the RNA equivalent of
0.02 (for AR-V1) to 12 (for AR-V9) VCaP cells in the
final RT–qPCR (Table S2). For the intralaboratory
validation, ddCq AR and its splice variants results
were generated by five different technicians, starting at
the RNA isolation step. No significant differences were
observed between the data generated by the different
technicians (Kruskal–Wallis test P > 0.05) (Table S3).
For the interlaboratory validation, RNA extracted
from five different cell lines and CTC fractions of 10
different patients with unknown AR status were
exchanged between two laboratories (Rotterdam and
Antwerp). For both the cell line and clinical samples,
similar outcomes for AR and its splice variants were
obtained (Table S4).
2.4. Normalization and statistical analysis
Evaluation of the RT–qPCR data was performed as
described in full detail before (Sieuwerts et al., 2018).
In brief, only those samples with (a) an average Cq of
the reference genes GUSB, HMBS, and HPRT1 < 26.5
(indicating sufficient overall RNA quality and
quantity) and (b) an average Cq of the epithelial genes
EPCAM and KRT19 < 26.0 (indicating sufficient
epithelial tumor cell input) were selected for the analy-
ses. All Cq values were normalized to the average Cq
value of the two epithelial genes to avoid confounding
of the analyses by the number of CTCs present in a
sample. As established before for AR-V7 (Sieuwerts
et al., 2018), samples were considered to be positive
for any of the AR variants if a positive signal was
detected within 8.5 cycles after the epithelial signal was
detected. To ensure data were comparable in-between
experiments, a calibrator consisting of total RNA from
cultured VCaP prostate cancer cells was included in
each RT–qPCR session and processed identically to
the samples. To calculate the calibrator normalized
messenger ribonucleic acid (mRNA) expression level of
the target, the delta–delta Cq (ddCq) method was used.
The primary endpoint of this study was the differ-
ence in CTC response rate (CTC-RR), either defined
as a conversion from ≥ 5 CTCs/7.5 mL to < 5 CTCs
during treatment (CTC5) (de Bono et al., 2008) or a
clearance from ≥ 1 CTC (s) to 0 during treatment
(CTC0) (Heller et al., 2017), between patients with
CTCs positive for one of the AR-Vs and patients with
CTCs negative for the particular AR-V splice variant
at baseline. Secondary objectives comprised prostate-
specific antigen (PSA)-RR (30% and/or 50% decline
from baseline to 12 weeks) and OS by the different
AR-Vs. No formal sample size calculations were per-
formed since we were restricted to the inclusion of
patients from the CABARESC trial who consented for
additional blood sampling for CTCs. Therefore, our
analyses should be considered exploratory.
Standard statistical tests were applied to address the
objectives. Differences between patient groups were
tested by chi-square or Fisher’s exact test. Survival
was calculated from the registration date in the
CABARESB trial, that is, start with cabazitaxel, until
the date of death or last contact in the case of baseline
parameters and from the time of second blood sam-
pling until date of death or last contact for the on-
study parameters. The survival analyses were con-
ducted using univariate and multivariate (with back-
ward stepwise selection) Cox regression models. For
the post-treatment OS analyses, we conducted land-
mark analyses to compensate for the 6-week treatment
by removing the patients which experienced an event
prior to the 6-week landmark and then resetting the
time to zero at the landmark. All statistical tests were
two-sided. Bootstrapping and a stringent P value
< 0.01 were applied to correct for multiple testing.
Statistics were performed using SPSS 24.0 (IBM Corpo-
ration, Armonk, NY, USA).
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3. Results
3.1. Patient characteristics
For the current analyses, we selected all n = 124
patients that had been included in the prospective
CABARESC trial (Nieuweboer et al., 2017) and who
had consented for additional blood sampling. Figure 1
shows the selection of patients and evaluable samples.
Patient characteristics for the finally clinically evalu-
able n = 118 patients and n = 104 patients with an
evaluable AR profile are summarized in Table 1 and
specified for all n = 124 patients which gave informed
consent for additional blood sampling in Table S5. All
patients had been previously treated with docetaxel,
and one-third had also received next-generation AR-
targeted agents (Table 1, left column). As expected,
patients with sufficient epithelial cell input in the base-
line blood sample, indicating the presence of CTCs in
the sample (evaluable patients with epithelial signal),
had worse baseline prognostic characteristics (higher
LDH, AP, PSA and CTC count) than the patients
with a low or absent epithelial signal in the blood sam-
ple (HBD-like patients, Table 1, left columns).
Consistent with our previous studies reporting on a
subset of this cohort (Onstenk et al., 2015; Sieuwerts
et al., 2018), AR-V7 was detected in 48% (25 out of
52) of the evaluable baseline samples. Of the 12
patients previously treated with abiraterone or
enzalutamide, 6 (50%) expressed AR-V7 at baseline
compared with 19/40 patients (48%) who had not
received prior abiraterone or enzalutamide (P = 1.00,
Table 1, right columns).
3.2. Prevalence of the AR-Vs
Ninety-nine samples were evaluable for the splice-vari-
ant analyses; 52 were baseline samples and 47 were fol-
low-up samples taken after the second cycle of
cabazitaxel. Evaluable sample pairs to assess changes
in AR-V status during cabazitaxel were available for
26 patients.
The prevalence of full-length AR and the four AR-
Vs in the baseline and follow-up samples is shown in
Table 2. Whereas 98% of the baseline patients were
positive for AR-FL, the detection rates for AR-V1,
AR-V3, AR-V7, and AR-V9 were lower at 31%, 31%,
48%, and 42%, respectively. Twenty-four of the 36
(67%) patients positive for one AR-V co-expressed at
least one other AR-V. After two cycles of cabazitaxel,
96% of the patients remained positive for AR-FL, the
variants AR-V1, AR-V3, AR-V7, and AR-V9 were
detected in 30%, 19%, 40%, and 32% of the patients,
respectively. Twenty-six of the 36 patients positive for
one AR-V co-expressed at least one other AR-V (50%
of all patients, Table 2, right panel; Table S5). Except
for AR-V9, loss of expression during cabazitaxel treat-
ment was more frequently observed than a gain, albeit
not statistically significant (Table 2, bottom panel).
All paents included in the 
CABARESC trial
N = 246
No consent for addional 
blood sampling
N = 122
Paents from parcipang 
centers who gave consent 
for blood sampling
N = 124
Screen failure N = 2
Protocol violaon N = 2
Clinically evaluable baseline paents
N = 118
Mean Cq reference genes > 26.5 
N = 11
Mean Cq epithelial genes > 26.0 
N = 52
Mean Cq reference genes > 26.5 
N = 5
Mean Cq epithelial genes >  26.0 
N = 45
Evaluable baseline samples
N = 52
Evaluable follow-up samples
N = 47
No EDTA blood received or > 24 
h at baseline N = 2
No sample N = 3 No sample N = 21
Screen failure N = 2
Protocol violaon N = 3
No EDTA blood received or > 24 
h at follow-up N = 1
Clinically evaluable follow-up paents 
aer 2nd cycle of cabazitaxel
N = 118
No consent for addional 
blood sampling
N = 122
BASELINE SAMPLES FOLLOW-UP SAMPLES
Fig. 1. Selection of evaluable patients for the analyses.
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Table 1. Patient characteristics. Patient characteristics of all patients with at least one available blood sample (N = 118 from the total of
124, first column) and the evaluable patients for the analyses with a baseline blood sample containing sufficient reference and epithelial
gene signal (N = 52, patients with epithelial signal, third column) and non-evaluable patients with insufficient epithelial signal, indicating the
absence of tumor cell signal (N = 52, HBD-like patients, second column); P values in the fourth column are from the comparisons between
the evaluable and excluded patients. The fifth and sixth columns show the characteristics of evaluable patients with AR-V7 negative CTCs
(N = 27) or AR-V7 positive CTCs (N = 25) at baseline; P values in the last column are from the comparisons between the patients with AR-
V7 positive and negative CTCs, respectively. All P values are from non-parametric Mann-Whitney U test (for age, baseline chemistry and
CTC counts) and Fisher exact tests for the categorical variables.
All patients
HBD-like
patients
Patients
with
epithelial
signal P value
AR-V7-
negative
patients
AR-V7-
positive
patients
P
value
N 118 100% 52 100% 52 100% 27 100% 25 100%
Mean age (years  SD) 69  7 71  7 69  7 0.17a 70  8 68  7 0.23a
WHO performance status
0 60 51% 28 54% 26 50% 0.84b 13 48% 14 56% 1.00b
1 58 49% 24 46% 26 50% 14 52% 12 48%
N prior chemotherapy lines
1 112 95% 50 96% 48 92% 0.68b 27 100% 21 84% 0.047b
2 6 5% 2 4% 4 8% 0 0% 4 16%
Prior antiandrogens
None 75 64% 33 63% 34 65% 16 59% 18 72%
Orteronel 23 19% 3 6% 6 12% 0.74b 5 19% 1 4% 0.19b
Abiraterone 8 7% 14 27% 7 13% 0.14b 2 7% 5 20% 0.24b
Enzalutamide 11 9% 1 2% 5 10% 0.44b 4 15% 1 4% 0.35b
Both orteronel and enzalutamide 1 1% 1 2% 0 0% 0 0% 0 0%
With budesonide
No 63 53% 25 48% 33 63% 0.17b 17 63% 16 64% 1.00b
Yes 55 47% 27 52% 19 37% 10 37% 9 36%
Baseline chemistry
Lactate dehydrogenase (median, IQR) 312 (216–
454)
270 (200–
372)
371 (250–
575)
0.002a 335 (224–
671)
396 (275–
554)
0.89a
Alkaline phosphatase (median, IQR) 128 (84–
240)
122 (79
162)
174 (98–
339)
0.009a 150 (68–
368)
192 (127–
310)
0.16a
Prostate-specific antigen (median, IQR) 149 (49–
365)
106 (35–
298)
209 (72–
510)
0.046a 186 (64–
500)
232 (77–
707)
0.46a
Circulating tumor cells N = 112 N = 51 N = 50 N = 26 N = 24
Median (IQR) 16 (3–95) 7 (1–19) 83 (8–230) < 0.0001a 48 (5–230) 98 (35–
243)
0.46a
CTCs > 0 97 87% 39 76% 49 98% 0.59b 26 100% 23 96% 0.48b
CTCs ≥ 5 76 68% 28 55% 40 80% 0.010b 20 77% 20 83% 0.73b
Cycles of cabazitaxel received (median, IQR) 7 (4–9) 8 (4–10) 6 (3–8) 6 (3–8) 6 (3–8)
Abiraterone/enzalutamide after cabazitaxel
No 47 40% 22 42% 22 42% 13 48% 9 36%
Abiraterone 28 24% 10 19% 13 25% 0.80b 8 30% 5 20% 1.00b
Enzalutamide 33 28% 15 29% 13 25% 0.81b 3 11% 10 40% 0.08b
Both 9 8% 5 10% 4 8% 1.00b 3 11% 1 4% 0.64b
Follow-up CTC count N = 100 N = 42 N = 45 N = 23 N = 22
Interval between start of cabazitaxel and second
count (median weeks, IQR)
6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6) 6 (6–6)
Circulating tumor cells (median, IQR) 8 (1–44) 6 (0–27) 15 (2–123) 0.025a 10 (1–79) 29 (2–125) 0.45a
CTCs > 0 76 76% 30 71% 36 80% 0.45b 18 78% 18 82% 1.00b
CTCs ≥ 5 54 54% 22 52% 28 62% 0.39b 14 61% 14 64% 0.73b
aMann–Whitney U-test.
bFisher’s exact test.
Bold values indicate significant values.
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3.3. CTC count and AR-Vs
No statistically significant association (P < 0.01) was
observed between AR-Vs and any of the baseline
clinical parameters, including prior anti-AR-targeted
treatment (Table S6). After correction for sufficient
epithelial signal, only patients positive for either AR-
V1 or AR-V9 had higher median baseline CTC
counts as measured in parallel from the enumeration
tube. Only patients positive for AR-V3 also had
higher median CTC counts after the second cycle of
cabazitaxel.
Table 2. Prevalence of AR-FL and the four AR splice variants at base line and follow-up. Detection of different splice variants in the
evaluable samples at baseline (upper panel) and after the second cabazitaxel cycle (lower row). The right panel shows the presence of
multiple AR-V in one sample at a specific time point. The lower panel shows the changes in positivity for the different AR-Vs during
cabazitaxel treatment; no significant differences in the directions of changes were observed. Percentages in the cross tables may not add
up to exactly 100% due to rounding.
N AR-FL AR-V1+ AR-V3+ AR-V7+ AR-V9+
Number of patients with positive AR-Vs
0 1 2 3 4
Positive at
baseline
52 51 98% 16 31% 16 31% 25 48% 22 42% 16 31% 12 23% 10 19% 9 17% 5 10%
Positive after
c2
47 45 96% 14 30% 9 19% 19 40% 15 32% 21 45% 7 15% 10 21% 6 13% 3 6%
Overlapping
baseline vs c2
26
Remain pos 25 96% 6 23% 3 12% 8 31% 10 38%
Pos --> Neg 1 4% 5 19% 9 35% 6 23% 1 4%
Neg --> Pos 0 0% 3 12% 2 8% 4 15% 5 19%
Remain neg 0 0% 12 46% 12 46% 8 31% 10 38%
McNemar for
change during
treatment
1.00 0.73 0.06 0.75 0.22
c2; after the 2nd cycle of cabazitaxel.
Table 3. Correlations between CTC count, AR-FL and the AR-Vs. Spearman correlation coefficients and corresponding P values from the
correlations between the CTC count, AR-FL, and the four AR-Vs at baseline (top panel) and during follow-up after the second cycle of
cabazitaxel chemotherapy (bottom panel).
Baseline [N = 50a/ N = 52]
CTC counta AR-FL AR-V1 AR-V3 AR-V7 AR-V9
rs P rs P rs‘ P rs P rs P rs P
AR-FL 0.03 0.84
AR-V1 0.43 < 0.01 0.23 0.11
AR-V3 0.24 0.10 0.36 < 0.01 0.31 0.02
AR-V7 0.01 0.96 0.14 0.33 0.00 0.99 0.06 0.69
AR-V9 0.29 0.04 0.11 0.45 0.30 0.03 0.22 0.11 0.45 < 0.01
Follow-up [N = 47]
CTCcount AR-FL AR-V1 AR-V3 AR-V7 AR-V9
rs P rs P rs P rs P rs P rs P
AR-FL 0.42 < 0.01
AR-V1 0.37 0.01 0.36 0.01
AR-V3 0.10 0.49 0.29 0.05 0.16 0.29
AR-V7 0.35 0.02 0.50 < 0.01 0.62 < 0.01 0.38 < 0.01
AR-V9 0.47 < 0.01 0.30 0.04 0.33 0.02 0.14 0.35 0.44 < 0.01
Spearman rank correlation test; 2-sided P-values < 0.01 were considered statistically significant.
aFor 50 of the n = 52 patients, a CTC count was available.
Bold values indicate significant values.
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The correlations in ddCq values between the AR-Vs,
AR-FL, and the CTC counts are shown in Table 3.
Noteworthy, both at baseline and at follow-up, there
were no significant correlations between AR-V3 and -
V7 and CTC count. At baseline, only AR-V1 corre-
lated with CTC count, and in the on-treatment sam-
ples, this was only the case for AR-FL and AR-V9.
Furthermore, at baseline only AR-V3 correlated with
AR-FL, while AR-V7 correlated with the presence of
AR-V9. Interestingly, the strength of the observed cor-
relations between AR-V7 and the other splice variants
was stronger in the on-treatment blood samples.
3.4. Association with CTC and PSA response
First, we evaluated the CTC5- and CTC0-RR after
two cycles of cabazitaxel (defined as a conversion from
≥ 5 CTCs/7.5 mL to < 5 CTCs or a clearance from
≥ 1 CTC(s) to 0 during treatment, respectively). The
overall CTC5-RR in the 43 evaluable patients was
35%; the overall CTC0-RR for these patients was
16%. No significant differences at our multiple correc-
tion adjusted P < 0.01 were seen in both CTC-RRs by
AR-FL, AR-V1, AR-V3, and AR-V7 status (Table 4).
Only patients with AR-V9-positive CTCs at baseline
less frequently achieved a CTC5-RR response, associ-
ating the presence of AR-V9-positive CTCs at baseline
with poor outcome to cabazitaxel (Table 4, upper
panel). Next, we evaluated the PSA response. None of
the splice variants associated with PSA response as
measured at 12 weeks (Table 4, lower panel).
3.5. Association with overall survival
Lastly, we investigated the impact on OS of the pres-
ence of the AR-Vs, at baseline and after two cabazi-
taxel cycles, respectively. Median OS for the n = 52
baseline patients was 8.3 months (95% CI: 7.1–13.0)
and 7.7 (95% CI: 7.0–10.6) for the n = 47 patients at
follow-up.
At baseline, the AR-V1 status and CTC count asso-
ciated with decreased OS in the univariate model. Mul-
tivariate Cox regression analyses showed that at
baseline only CTC count remained an independent
poor prognostic factor for OS (Table 5, upper panel).
AR-FL, AR-V1, and CTC count measured after two
cycles of cabazitaxel, and anti-AR treatment after
cabazitaxel, associated with OS in the univariate
model. In the multivariate model, CTC count
remained an independent prognostic factor. AR-V1
status overruled AR-FL and was an additional CTC5-
independent predictive factor for OS after two cycles
of cabazitaxel (Table 5, bottom panel). The OS curves
as a function of AR-V1 in CTCs after two cycles of
cabazitaxel are shown in Fig. 2.
4. Discussion
Whereas the presence of AR-FL and the constitutively
ligand independent active AR-V3 and AR-V7 were
not associated with outcome to therapy, the presence
of the conditionally activated AR-V9 and AR-V1
associated with a negative CTC RR during treatment
and decreased OS after two cycles of cabazitaxel,
respectively. In this study, we demonstrated in an
extended cohort of metastatic prostate cancer patients
that the presence of AR-V7 in CellSearch-enriched
CTCs is not associated with outcome to cabazitaxel.
In line with our previous findings in the first 29
patients with ≥ 10 CTCs we studied at baseline
(Onstenk et al., 2015), we detected AR-V7 at baseline
in 48% of all the 52 evaluable patients. We did not
find a correlation between the presence of AR-V7 at
baseline and prior anti-AR-targeted therapy. After
the second cycle of cabazitaxel, the prevalence of AR-
V7 had slightly but not significantly decreased from
48% to 40%, indicating that expression of AR-V7
was neither specifically lost nor gained during treat-
ment with cabazitaxel.
To investigate whether other AR splice variants than
AR-V7 were associated with response or outcome to
cabazitaxel, we similarly analyzed the expression levels
of another variant with constitutive activity (De Laere
et al., 2017; Jernberg et al., 2017) (AR-V3) and two more
cell–context-dependent variants (AR-V1 and AR-V9)
(Hu et al., 2009; Hu et al., 2011; Jernberg et al., 2017) in
CTCs of mCRPC patients at baseline and after 2 cycles
of cabazitaxel.
Perhaps surprisingly, taking our associations with
outcome to cabazitaxel only associated with the condi-
tionally activated AR-V1 and AR-V9 into account, we
noticed a positive correlation between AR-V7 and AR-
V9 at baseline and AR-V7 and all studied splice vari-
ants after two cycles of cabazitaxel. However, although
the presence of AR-V1, AR-V3, AR-V7, and AR-V9 in
CTCs at baseline and during cabazitaxel treatment
was frequently observed in our study, only 10% of the
patients co-expressed all four AR-Vs at baseline and
6.5% after two cycles of cabazitaxel, suggesting the
presence of an AR splice variant at our indicated cut-
offs is a splice-variant-specific event.
Importantly, concern has been shared that the detec-
tion of AR splice variants might be intrinsically related
to CTC count. However, after using our cutoffs and
adjusting for the epithelial content present in the blood
samples, at baseline only AR-V1 and at follow-up only
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AR-FL and AR-V9 correlated significantly with CTC
count.
Confirming our prior observations (Onstenk et al.,
2015), we found no associations between the AR-V7
status and outcome to cabazitaxel in terms of the
CTC/PSA-RR and/or OS. Similarly, the other consti-
tutively activated AR variant we investigated, AR-V3,
had no association with these outcome measures. In
contrast, the presence of the conditionally activated
AR-V1 showed an association with OS at baseline and
after two cycles of cabazitaxel; patients with positive
CTCs for the other conditional variant, AR-V9, associ-
ated with CTC5 response to cabazitaxel, but we found
no impact of the presence of AR-V9 on OS. A lower
sensitivity of our assay to detect AR-V9 could explain
the lack of an association (although the LODs) were
with the equivalent of 0.11 cells comparable for the
two assays, the LOQ was the equivalent of 0.02 cells
for AR-V1 and 12 cells for AR-V9; see also Table S2).
Interestingly, the presence of AR-V1 in CTCs was a
poor prognostic factor for OS at baseline, but this
might merely have been a reflection of CTC count.
After the second cabazitaxel cycle, the presence of AR-
V1 kept its prognostic value. And at this time point,
the presence of AR-V1 was, together with high CTC
count, an independent factor for worse OS in our mul-
tivariate analysis.
The results from our study compare well with recent
reports on the clinical value of the AR-V7 status of
CTCs. The observed AR-V7 positivity rate of 48% at
baseline in this study is similar to the previously
reported 18–46% (Antonarakis et al., 2015; Antonara-
kis et al., 2014; De Laere et al., 2017; Miyamoto et al.,
2015; Scher et al., 2016). The lack of association
between the AR-V7 status of CTCs and outcome to
taxane-based chemotherapy confirms both our prior
findings (Onstenk et al., 2015), as well as those of
others (Antonarakis et al., 2015; Scher et al., 2018).
On the contrary, an association has been reported
between the presence of AR-V7 at the protein level
and worse outcome to taxane treatment, especially
when the protein was localized in the cell nucleus
(Scher et al., 2017; Scher et al., 2016; Tagawa et al.,
2019). Nonetheless, the negative impact on outcome to
anti-AR treatment was with an hazard ratio (HR) of
10.4 much higher than the HR of 3.2 for taxane treat-
ment (Scher et al., 2017; Scher et al., 2016). The possi-
ble differences in functionality and clinical relevance of
overall mRNA levels vs translated protein levels of
AR-V7 need further investigation.
In line with our observations, switches in the AR-V7
status of CTCs during treatment have been reported.
In a small group of just 14 patients, a loss of AR-V7
only occurred during taxane treatment and not during
Table 5. AR-Vs correlated with overall survival. Univariate (left columns) and multivariate (right columns) Cox regression analyses for the
associations of baseline parameters (upper rows) and on-study parameters (lower rows) with OS. For the on-study parameters, survival time
was calculated from the second blood draw. The multivariate Cox regression analysis was carried out using backward selection. Non-
significant factors were removed stepwise and the HRs and P values were taken from the removal step.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Baseline (N of cases = 52)
AR-FL, continuous 1.0 0.9–1.1 0.90
AR-V1, positive vs negative 1.9 1.0–3.6 0.04 1.3 0.7–2.6 0.42
AR-V3, positive vs negative 1.9 1.0–3.5 0.06
AR-V7, positive vs negative 1.2 0.7–2.1 0.57
AR-V9, positive vs negative 1.5 0.8–2.8 0.17
CTC count, ≥5 vs < 5 CTCs 4.8 2.0–11.4 0.001 4.3 1.8–10.6 0.001
PSA, continuous 1.0 1.0–1.0 0.59
Anti-AR prior to cabazitaxel, yes vs no 1.4 0.8–2.6 0.26
After two cabazitaxel cycles (N of cases = 47)
AR-FL, continuous 1.2 1.0–1.3 0.005 1.1 0.9–1.2 0.30
AR-V1, positive vs negative 3.0 1.5–6.3 0.003 2.4 1.1–5.1 0.031
AR-V3, positive vs negative 1.7 0.8–3.7 0.16
AR-V7, positive vs negative 1.8 0.9–3.4 0.08
AR-V9, positive vs negative 1.6 0.8–3.2 0.19
CTC count, ≥5 vs < 5 CTCs 3.5 1.6–7.4 0.001 2.4 1.0–5.9 0.047
PSA at 12 weeks, continuous 1.0 1.0–1.0 0.17
Anti-AR after cabazitaxel, yes vs no 0.4 0.2–0.8 0.009 0.6 0.3–1.1 0.11
Bold values indicate significant values.
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anti-AR treatment (Nakazawa et al., 2015). We found
6 of 14 patients (43%) with AR-V7-positive CTCs at
baseline who reverted to AR-V7 negative during cabaz-
itaxel (Table 2). Similar high percentages were seen for
the other constitutively active AR-V3 (75%). For the
conditionally active AR-V1 and AR-V9, these fractions
were less with 45% and 9%, respectively. Given the
negative impact of the presence of AR-V7 on outcome
to anti-AR-targeted compounds (Antonarakis et al.,
2015; Antonarakis et al., 2014; Scher et al., 2016), one
may hypothesize that a loss of AR-V7 and perhaps
AR-V3 during chemotherapy translates to a regained
sensitivity to anti-AR treatments. However, this
hypothesis needs to be tested.
To the best of our knowledge, only two studies
reported on the clinical relevance of the presence of
other AR-Vs besides AR-V7 in the CTCs of patients
with mCRPC (De Laere et al., 2017; De Laere et al.,
2019). In the first study (De Laere et al., 2017), charac-
terization of circulating tumor DNA and CTCs from
30 mCRPC patients showed a correlation between the
presence of structural variants in the AR gene and
AR-Vs. In the second, larger study of the same group
(De Laere et al., 2019), the prognostic value of differ-
ent AR-Vs prior to starting first-line abiraterone and
enzalutamide treatment was investigated and demon-
strated that TP53 inactivation was an independently
associated negative response biomarker, while AR and
its splice variants were not. The authors concluded
that further comprehensive AR profiling studies are
required to determine which patients have a relevant
AR biomarker output. Besides, preclinical studies show
evidence for dimerization and interactions between dif-
ferent AR-Vs, such as AR-V7 and AR-V1 (Zhan et al.,
2017), as well as cross-reactivity of assays between dif-
ferent AR-Vs, such as AR-V7 and AR-V9 (Kohli et al.,
2017). Mutual correlations and individual biological
functions of the different AR-Vs as well as assay speci-
ficity will thus need to be studied in more detail and
will be the subject of a planned future study from our
group.
A major advantage of our CellSearch-based assay to
measure the expression of a panel of AR-Vs and AR-
FL in CTCs as opposed to assays like the AdnaTest
(Qiagen) is that it provides the possibility to obtain a
CTC count in parallel to the CTC characterization.
Importantly, our qPCR-based characterization assay
incorporates a correction for the number of CTCs pre-
sent in a sample by use of the expression levels of
epithelial genes to limit confounding of the analyses by
the CTC count. Both the CTC count and CTC
dynamics during treatment have robustly been shown
to be strongly associated with outcome (de Bono
et al., 2008; Scher et al., 2015; Scher et al., 2009).
The recruitment of patients from a clinical trial pro-
vided us with a homogeneous group of patients and
HR (95% CI); 3.2 (1.5–6.5)
P = 0.002
Median (95% CI)
AR-V1  negave 9.0 (5.0–13.0)
AR-V1 posive 3.7 (0.8–6.6)
C
um
ul
at
iv
e 
ov
er
al
l s
ur
vi
va
l
Paents at risk
AR-V1 negave 33 13 6 1 0
AR-V1 posive 14 2 0 0 0
1.0
0.8
0.6
0.4
0.2
0.0
0 10 20
Overall survival from second CTC sample (months)
30 40
Fig. 2. Overall survival as a function of AR-V1 in circulating tumor cells after two cycles of cabazitaxel. The reported P-value is from a log-
rank test and the test statistics from Cox regression analyses.
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samples with corresponding, prospectively collected,
clinical data. Only patients with sufficient epithelial
input in the sample were selected for the analyses to
ascertain reliable results from the AR-V assays. A
higher median baseline CTC count of 83 vs seven
CTCs/7.5 mL blood was detected in the evaluable
patients vs the excluded patients with an epithelial sig-
nal too low for a reliable AR-V assessment (Sieuwerts
et al., 2018), respectively, which supports the robust-
ness of our assay in measuring tumor-driven signals.
The main limitation of this prospective study is the
modest sample size. No formal sample size calculations
were performed and the exclusion of 50% of the
patients based on insufficient epithelial signal in the
samples for a meaningful AR-V analysis limits the
power of our analyses. To diminish the chance of type
I errors, we applied multiple testing corrections by
bootstrapping and employing a more stringent P value
< 0.01. Validation of our results in other retrospective
and prospective studies is warranted. Other blood-
based assays, for example on exosomes (Del Re et al.,
2017) or whole blood (Liu et al., 2016; Qu et al.,
2017), may in this context aid in reporting the AR-V
status in a larger proportion of patients, including
those without or with low number of CTCs.
5. Conclusions
In conclusion, we confirm that the presence of AR-V7
has no impact on outcome to cabazitaxel treatment in
patients with mCRPC. We found that the presence of
other AR-Vs, in particular AR-V1 and AR-V9, though,
may predict adverse outcome in terms of survival after
cabazitaxel and CTC-RR during treatment, respec-
tively. Especially our analysis showing that the CTC-
adjusted AR-V1 detection after two cycles of cabazi-
taxel was an independent prognostic factor for OS is a
potentially promising finding. Future studies on the
functionality and clinical relevance of different AR-Vs
are currently being set up in order to increase our
knowledge and understanding. A prospective clinical
study on the predictive value of the AR-V7 status of
CellSearch-enriched CTCs is currently ongoing
(NCT03050866).
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Table S1. Details Taqman gene expression assays.
Table S2. Limit of detection and limit of quantifica-
tion for the AR-V assays. Experiments were performed
as described before for AR-V7 (Sieuwerts et al., 2018).
In brief, the limit of detection (LOD), defined as the
lowest input of RNA isolated from VCaP cells that
could be reliably identified as being qualitatively pre-
sent in the sample, was calculated to be the RNA
equivalent of 0.03 (for AR-WT) to 0.5 (for AR-V3)
VCaP cells in the final RT–qPCR. The limit of quan-
tification (LOQ), defined as the lowest input of RNA
isolated from VCaP cells that could be reproducibly
quantified, was set at a CV of less than 25% and cal-
culated to be equal to the RNA equivalent of 0.02 (for
AR-V1) to 12 (for AR-V9) VCaP cells in the final RT–
qPCR.
Table S3. Intralaboratory validation for the AR-V
assays on paired clinical samples. Experiments were
performed as described before for AR-V7 (Sieuwerts
et al., 2018).
Table S4. Interlaboratory validation for the AR-V
assays. Experiments were performed as described
before for AR-V7 (Sieuwerts et al., 2018).
Table S5. Patient characteristics of all 124 patients
participating to the CTC study as shown in Fig. 1.
Table S6. Extension of Table 1, now also including
comparisons between the patient groups with CTCs
negative or positive for the other AR-Vs besides AR-
V7.
Data S1. In- and exclusion criteria for participation in
CABARESC trial.
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